TCF7L2 polymorphism associates with new-onset diabetes after transplantation. - Individual Prediction and Prevention of Risks of Immunosuppressive Therapies in Transplantation Access content directly
Journal Articles Journal of the American Society of Nephrology Year : 2009

TCF7L2 polymorphism associates with new-onset diabetes after transplantation.

Abstract

New-onset diabetes after transplantation (NODAT) is a serious and frequent complication in transplant recipients. Whether NODAT shares the same susceptibility genes as type 2 diabetes is unknown. In this multicenter study, we genotyped 1076 white patients without diabetes at transplantation for 11 polymorphisms that associate with type 2 diabetes. We defined NODAT as a fasting plasma glucose > or =126 mg/dl on at least two occasions or de novo hypoglycemic therapy. We compared clinical and genetic factors between patients who developed NODAT within 6 mo of transplantation (n = 118; incidence 11%) and patients without diabetes (n = 958). In multivariate analysis, NODAT significantly associated with the following characteristics: TCF7L2 polymorphism (odds ratio [OR] 1.60 per each T allele; P = 0.002), age (OR 1.03 per year; P < 0.001), body mass index at transplantation (OR 1.09 per unit; P < 0.001), tacrolimus use (OR 2.26; P < 0.001), and the occurrence of a corticoid-treated acute rejection episode (OR 2.78; P < 0.001). In summary, our data show that the TCF7L2 rs7903146 polymorphism, a known risk factor for type 2 diabetes in the general population, also associates with NODAT.

Domains

Immunology

Dates and versions

hal-00452833 , version 1 (03-02-2010)

Identifiers

Cite

Lidia Ghisdal, Christophe Baron, Yannick Le Meur, Arnaud Lionet, Jean-Michel Halimi, et al.. TCF7L2 polymorphism associates with new-onset diabetes after transplantation.. Journal of the American Society of Nephrology, 2009, 20 (11), pp.2459-67. ⟨10.1681/ASN.2008121314⟩. ⟨hal-00452833⟩
73 View
0 Download

Altmetric

Share

Gmail Facebook X LinkedIn More